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Abstract
Our objective was to estimate prevalence of current or ever use of a gluten free diet (GFD) in 
children aged 30–68 months with autism spectrum disorder (ASD) and population controls (POP); 
and to identify characteristics associated with ever having used GFD among children with ASD. 
We used data from the Study to Explore Early Development (SEED), a multi-site, case-control 
study of children with ASD. Caregivers reported GFD use by their children through structured 
questionnaires about diet patterns, gastrointestinal issues, and ASD-specific treatments. Prevalence 
was estimated and compared using log-Poisson regression, adjusting for confounders. In children 
with ASD, we examined whether child or mother’s gastrointestinal conditions or child’s 
phenotypic traits were associated with ever trying a GFD. In SEED, 71 children with ASD (11.1% 
prevalence after adjustment) were on a GFD at time of the study and 130 (20.4%) had ever used a 
GFD, a greater percentage than in POP children (N=11, 0.9% current use). Of current users with 
ASD, 50.7% had a dietary intervention that was prescribed by a medical professional. Among 
children with ASD, child gastrointestinal conditions and developmental regression were positively 
and independently associated with having ever used a GFD. Current use and ever use of a GFD 
were prevalent in children with ASD identified in SEED. GFD usage was associated with 
gastrointestinal issues and child phenotype. Clinicians may consider advising parents on how best 
to use these diets in the context of the child’s GI presentation and current scientific knowledge 
about effectiveness in relation to ASD symptoms.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by social 
communication deficits and repetitive and restrictive behaviors and interests (American 
Psychiatric Association, 2013). Most interventions for ASD are behaviorally based, but there 
is growing interest in dietary therapies that families believe may improve behavioral 
outcomes (Herbert & Buckley, 2013; Valicenti-McDermott et al., 2014; Whiteley, 2015). 
These therapies may reduce burden of other co-occurring conditions, such as gastrointestinal 
(GI) issues or conditions, which are prevalent in people with ASD (estimates range from 4.2 
to 96.8%) (Holingue, Newill, Lee, Pasricha, & Daniele Fallin, 2017). One such dietary 
therapy is a gluten free diet (GFD), which eliminates gluten, a protein found in wheat, 
barley, rye, and similar species and hybrids.
Because empiric evidence on the effectiveness of GFDs as an intervention for behavioral 
symptoms of ASD is weak and studies are few (Elder, Kreider, Schaefer, & de Laosa, 2015; 
Lange, Hauser, & Reissmann, 2015; Millward, Ferriter, Calver, & Connell-Jones, 2008; 
Sathe, Andrews, McPheeters, & Warren, 2017), it is important to understand which children 
(specifically of those without indications for a GFD like celiac disease) receive this type of 
alternative therapy as a way to better understand factors that influence the use of alternative 
therapies. The objective of this study was to estimate the prevalence proportion of current 
use or ever use of a GFD among children with ASD enrolled in the Study to Explore Early 
Development (SEED). Secondary objectives were to determine whether GFD use was 
associated with child traits like developmental regression, autism severity, and intellectual 
disability (ID), or with GI issues.
Methods
Design and participant ascertainment
SEED is a multi-site, community based, case-control study of ASD etiology and phenotypic 
correlates (Schendel et al., 2012). From 2007 to 2012, data were collected on children aged 
30 to 68 months who were born between September 1, 2003 and August 31, 2006 in one of 
six sites (California, Colorado, Georgia, Maryland, North Carolina, and Pennsylvania). Each 
site’s institutional review board and the Centers for Disease Control and Prevention review 
board approved the study protocol.
Children with ASD were identified through health and education agencies that provided 
diagnosis and services for children with ASD and other developmental disabilities or delays, 
and were invited to enroll in the study. ASD case status was confirmed by comprehensive 
evaluation (described below) as part of the study protocol. In addition, a sample of children 
born in the same years and regions were recruited from randomly sampled birth records to 
serve as population controls (POP)(Schendel et al., 2012).
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Developmental assessment
The child’s primary caregiver (the mother in 98% of participating families) completed the 
Social Communication Questionnaire (SCQ)(Rutter, Bailey, & Lord, 2003) during the 
enrollment phone call, and all children were asked to complete a general developmental 
evaluation that included the Mullen Scales of Early Learning (MSEL)(Mullen, 1995). To 
confirm ASD, children who screened positive on the SCQ (using a score ≥11 to indicate risk 
for ASD, which improves case finding in younger children) (Wiggins, Bakeman, Adamson, 
& Robins, 2007), had a past diagnosis of ASD, or were suspected to have ASD by a study 
clinician during the general developmental evaluation, were invited to participate in a full 
ASD evaluation.
During the full ASD evaluation, clinicians completed the Autism Diagnostic Interview-
Revised (ADI-R)(Rutter, Le Couteur, & Lord, 2003) with the child’s primary caregiver and 
the Autism Diagnostic Observation Schedule-2 (ADOS)(Lord, Rutter, DiLavore, & Risi, 
2012) with the child. An algorithm based on standard scoring for those measures was used 
to determine final case status as described in Wiggins et al, 2015 (Wiggins et al., 2015). 
Developmental regression, or a loss of previously acquired skills, was determined from the 
developmental regression item in the ADI-R. Child ASD severity was calculated using the 
ADOS total score, ADOS language level, and age at the evaluation (Wiggins et al., 2017). 
The ten-point scale was dichotomized into ‘less severe’ (scores of 4-7) and ‘more severe’ 
(scores of 8-10). Intellectual Disability (ID) was determined if a child scored ≤70 on the 
composite score of the MSEL (Mullen, 1995).
Gluten free diet
We defined a GFD as the purposeful restriction of gluten or carbohydrates from a child’s 
diet. We included diets that eliminate carbohydrates since they remove gluten by definition, 
although not all GFDs exclude all carbohydrates. Diets that eliminate casein, a protein found 
in dairy, are also common in conjunction with a GFD; however, our operational definition 
was based on any GFD, regardless of other dietary restrictions.
Current use—We determined GFD use at time of study participation (current use) by a 
GI-specific questionnaire asking all primary caregivers (both ASD cases and POP controls) 
if the child was currently on a restricted diet. If they answered yes, they were asked to 
describe the restrictions in an open-ended question. They were also asked whether the 
child’s diet was self-restricted, parent-restricted, or medically prescribed (although data 
were not collected to confirm that the prescribed diet was a GFD or who prescribed or 
suggested the diet). Text responses were manually examined and if the text indicated GFD or 
a synonym (for example, ‘no gluten’) then children were classified as currently on a GFD.
Ever use—Caregivers of children with ASD completed an additional questionnaire on 
ASD-specific therapies and interventions and were asked ‘what special diet, vitamins, food 
supplements, alternative treatments, or interventions has your child ever received?’ We 
examined data from the text fields for any indication of a GFD. We combined past and 
current use to form an ever use GFD variable for the children with ASD.
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Other data collection
Demographic data were collected by caregiver interview and from the child’s birth 
certificate. Family medical history, including maternal history of any GI issues or of 
physician-diagnosed GI disorders (i.e., ‘Did the mother ever have/or has the condition: 
gastrointestinal disorders’ [yes/no]) and child’s history of immune-related GI (‘had the child 
ever had a diagnosis of celiac disease or non-celiac gluten sensitivity’), was ascertained 
through self-completed questionnaires. To identify children with GI problems, we used the 
caregiver’s report that the child currently or in the past had GI issues on a regular basis 
(specifically, vomiting, constipation, diarrhea, loose stool, painful stool, abdominal pain, 
gas, or other occurring more than twice a month [yes/no for each issue.
Our primary analysis included all children who had SEED-confirmed ASD or were POP 
controls that provided data on current dietary practices (N=1481). To examine ever use of a 
GFD, our sample was restricted to children with ASD who had additional data reflecting use 
of GFD prior to study participation.
Prevalence proportions for the ASD group and POP group for current use and the ASD 
group for ever use of GFDs were modeled using multi-level log Poisson regression. We ran a 
crude model (with site as a random intercept since it is a design variable) and a model that 
used inverse probability weights (Rothman, Greenland S., & Lash T.L., 2008) to adjust for 
confounders identified a priori (maternal age, race, ethnicity, education, and child year of 
birth), keeping site as a random intercept. Based on minimal missing covariate data (<1%) 
we ran complete case analyses. Because a child could have received the first diagnosis of 
ASD in SEED, and these children might have different dietary experiences than those with a 
previous history of the diagnosis, we additionally ran a sensitivity analysis restricted to 
children who had a history of an ASD diagnosis.
Among the ASD group, we ran multi-level log Poisson models, similarly weighted as in our 
prior model to control for confounding, to compare prevalence of ever use of GFD by the 
child’s developmental and family health characteristics: ID, developmental regression, ASD 
severity, child GI issues, and maternal GI issues. Because time and duration of GFD were 
not collected, we evaluated GFD use in association with phenotypic traits more likely to be 
stable with time. We evaluated the association between child and maternal GI issues and 
GFDs because GFD is often used to treat GI issues. We also stratified these analyses by 
whether the child had a history of GI issues to examine whether factors associated with GFD 
diet use were differentially associated with GI issues.
Results
We had adequate data to assess a child’s GFD use for 689 (95%) of the 722 children with 
ASD and 759 (77%) of 986 POP children. POP mothers without data were of similar race 
and slightly less educated compared to POP mothers with data. Among children with ASD, 
130 (18.8%) had ever use of a GFD and 71 had current use (10.3%). Of those current users, 
34 indicated current use only and 37 indicated both past and current use. In the ASD group, 
those with current or ever GFD use were more likely to have mothers who were white 
(77.5% of mothers of ever users compared to 58.2% of mothers of never users) or have a 
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bachelor’s degree or higher (65.1% of mothers of ever users compared to 48.6% of mothers 
of never users) than never users (Table 1). For children with ASD, 98% of ever users and 
82% of those who never used a GFD had a past diagnosis of ASD at SEED enrollment. Of 
children with ASD who were current users of a GFD, 36 (50.7%) were on a diet that was 
medically prescribed. Forty children with ASD who were not current using a GFD (6.4%) 
were on a medically prescribed diet at study entry. We did not have information on what 
type of professional prescribed the diet. In contrast, 11 POP children (1.1%) had current use 
of a GFD. Of theses 11, 88.9% had white mothers, 72.7% were males, 44.4% had mothers 
with a bachelor’s degree or higher, and none had ID. Among POP children who did not 
indicate current use of a GFD, 74.9% had white mothers, 64.9% had mothers with a 
bachelor’s degree or higher and 90.4% were not Hispanic. In our sample, no children had 
celiac disease based on parental report.
Among children with ASD, 11.1% were current users of a GFD after adjusting for 
confounding (95% confidence interval [CI]: 8.2, 14.8) (Table 2). By comparison, 0.9% of 
POP children were current users in our adjusted model (95% CI: 0.5, 1.8). The adjusted 
prevalence estimate for ever use among children with ASD was 20.4% (95% CI: 17.3, 24.1). 
In a sensitivity analysis limited to just children with past ASD diagnosis results were similar 
to our full sample results; current use was 12.9% (95% CI: 9.2, 18.0) and ever use was 
23.7% (95 CI: 19.1, 29.0).
Ever use of GFD was associated with developmental regression (prevalence ratio (PR): 1.70, 
95% CI: 1.23, 2.36) and child GI issues (PR 2.95, 95% CI: 2.31, 3.77) (Table 3). GFD was 
not associated with child ID, ASD severity, or maternal GI issues. However, among children 
with ASD and GI issues, ASD severity was associated with ever use of a GFD (PR 1.43; 
95% CI 1.01, 2.02) (Figure 1), while severity was not associated with ever use among 
children without GI issues (PR 1.11; 95% CI: 0.54, 2.29). In contrast, PRs for developmental 
regression were larger among children with ASD without GI issues (PR 2.53; 95% CI: 1.69, 
3.79) compared to those with GI issues (PR 1.57, 95% CI: 1.08, 2.28). Maternal GI issues 
and ID were not associated with use of a GFD in either stratum of child GI issues.
Discussion
GFDs were common in preschool aged children with ASD in SEED with 20.4% of having 
ever used a GFD and 11.1% using a GFD at study entry. Current use was significantly more 
prevalent among ASD cases compared to POP controls who had a prevalence of 0.9%. 
Among children with ASD, 55% of those who had ever used a GFD remained on GFD at the 
time of study participation. GFD use was associated with child GI issues and developmental 
regression.
When comparing these results to past estimates of GFD prevalence, it is important to 
account for differences in methods and child age. An online survey conducted in 2011 in 
Southern Virginia of 194 parents of children with ASD found 54.8% had ever initiated a 
GFD for their child (Hopf, Madren, & Santianni, 2016). The survey sampled from members 
of autism community organizations asking whether they used any diet modifications or 
restrictions for their child. If the answer was yes, they were asked whether the modification 
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or restriction was a gluten free-casein free diet, or a GFD. Average child age was 9.9 years 
(standard deviation of 4.4 years)(Hopf et al., 2016). The estimate for GFD use may have 
been higher because these children were older and had more time to try this type of diet. 
Another survey sampled 246 parents of children with ASD recruited through regional 
databases and parent support organizations and forums in the United Kingdom between 
2009 and 2010 and estimated that GFDs had been used by 31% of children aged 3-5 years 
(Winburn et al., 2014). Participation from specific parent forums or databases may reflect 
parents with similar approaches in trying therapies or, the group may have had shared 
communication about intervention effectiveness.
The results of our study of children aged 3–5 years reflect a broader sample from multiple 
sites, which adds demographic and phenotypic diversity. Because SEED recruited from a 
variety of clinical and educational sources, this estimate of GFD prevalence may reflect a 
broader population of individuals with ASD in this age category than would sampling from a 
particular setting or region. While SEED is unable to ascertain response proportions from 
the multi-source community sample, we adjusted analyses to control for potential 
socioeconomic differences in factors. Additional strengths of our study were the 
confirmation of ASD case status through gold standard developmental evaluation, and a 
sampling strategy that both confirmed case status and identified previously undiagnosed 
children, thus reducing potential for ASD misclassification that might reflect biases in 
access to health care and ASD case ascertainment.
Our study focused specifically on patterns of GFD use but was unable to assess the 
effectiveness of GFD for managing either ASD or GI symptoms. Prevalence of GFD use 
may be elevated as compared to POP controls because parents believe that reducing 
discomfort from GI issues can improve child behavior. GI issues in children with ASD are 
common (Hsiao, 2014; Ibrahim, Voigt, Katusic, Weaver, & Barbaresi, 2009) and GFDs are 
frequenty used as an alternative therapy for non-celiac GI issues, with some indication of 
success for irritable bowel syndrome (El-Chammas & Danner, 2011; Reilly, 2016). Our 
results showed a strong association between GFD and child history of GI issues, which may 
suggest that GFDs are tried in an attempt to alleviate these symptoms. The high prevalence 
of GI issues among children with ASD and the relative ease with which a parent can 
implement a dietary intervention may be a factor in the prevalence of GFDs. Although often 
expensive and hard to maintain (Elder et al., 2015), a GFD does not need a medical 
prescription or specialized training.
Reported celiac disease or gluten intolerance is no higher in children less than 10 years old 
with ASD than population controls (Ludvigsson, Reichenberg, Hultman, & Murray, 2013), 
but it has been hypothesized that a genetic condition among children with ASD might lead 
to a ‘leaky gut’ where gluten or casein creates an excess of peptides, causing behavioral 
symptoms common to ASD (Campbell et al., 2009; Elder et al., 2015; Reichelt & 
Knivsberg, 2009). Knowing that ASD behaviors may be related to the gut microbiome 
(Mangiola et al., 2016), parents or clinicians may decide to try this diet on children with 
ASD, regardless of the results of tests for these peptides. As yet, there have been only a few 
randomized controlled trials assessing effectiveness of a GFD as a tool to reduce behavioral 
symptoms, and among the studies that have been done, results lean toward no effect (Elder 
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et al., 2015; Hyman et al., 2016; Mari-Bauset, Zazpe, Mari-Sanchis, Llopis-Gonzalez, & 
Morales-Suarez-Varela, 2014; Millward et al., 2008; Navarro et al., 2015); however, few 
have addressed GI issues as a modifier in these trials (Elder et al., 2015). In our study, 50.7% 
of children with ASD who were current users of a GFD were on a diet that was prescribed 
by a medical professional (although data were not collected to confirm that the diet indicated 
was a GFD nor who was the prescriber). This percentage of children with a prescribed diet is 
high, given the lack of evidence supporting the efficacy of GFD use for reduction of ASD 
symptoms or GI symptoms in children with ASD. More information is needed to understand 
how these diets are discussed between clinicians and parents, given the often-difficult nature 
of diagnosing GI conditions in children with ASD (Buie et al., 2010) and the popularity of 
complementary treatments among parents (Valicenti-McDermott et al., 2014). Based on the 
current lack of knowledge and the uncertainty about efficacy communicating this uncertainty 
is important when GFD is discussed between parents and medical professionals.
We found that developmental regression was associated with ever use of a GFD. A study by 
Gadow et al. (2017) found that children with developmental regression were more likely to 
have a severe ASD presentation, and Patten et al. (Patten, Baranek, Watson, & Schultz) 
found that children with more severe presentations had tried more interventions. In our 
study, ever use of GFD was more likely in children with developmental regression and no GI 
issues than in children with developmental regression and GI issues. Despite limited 
scientific evidence for efficacy or effectiveness, parents often report that GFDs help improve 
child ASD symptoms such as social communication and interaction (Hopf et al., 2016; 
Winburn et al., 2014). It is possible that parents who report improvement in their child pass 
this information through social and support networks to other parents of children with ASD, 
increasing GFD usage. Although we did not have data on what motivated GFD usage, these 
results suggest that there could be at least three reasons for using this diet: 1) to reduce GI 
symptoms, 2) to reduce ASD specific symptoms, or 3) both.
Our study had some limitations that temper our conclusions. We did not collect data on date 
a GFD was initiated and length of time that it was used. This prevented us from exploring 
factors that preceded GFD use or average duration. Because data were collected at one point 
in time, we were unable to examine the impact of the GFD on child GI issues or ASD 
symptoms, or whether the parent found a GFD helpful. Further, data on child GI issues and 
GFD diet usage came from parent reports. Studies have reported wide ranges of GI issues in 
children with ASD that depends largely on method of data collection (Holingue et al., 2017; 
McElhanon, McCracken, Karpen, & Sharp, 2014). Our sample consisted of children who 
were 3–5 years old between 2007 and 2012. Our findings may not be generalizable to older 
children who may have more influence on their diet, or have had more time to try 
interventions, or to develop gluten intolerance. Because of this young age range, we were 
not able to evaluate the association between co-occurring conditions that may develop later 
in life, like epilepsy or obesity, and GFD initiation. Although we adjusted for the child’s 
year of birth and had a narrow age range, children differed in the amount of time that they 
could have used a GFD. Lastly, the time frame of our data collection may not have captured 
the boom in GFDs in the general population in the early 2010s (Reilly, 2016).
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Despite these limitations, SEED collected extensive data, allowing examination of GFD use 
and various developmental characteristics important for refining smaller ASD subgroups, 
which may be more or less likely to try or to benefit from particular therapies. Our sample 
was from a multi-site community-based study with confirmed ASD diagnosis, reducing 
potential biases associated with self-selection from online surveys or clinic-only samples. 
This study estimated prevalence for both current use and ever use, which provides insight 
into the frequency with which parents try and then abandon GFDs. Additional research is 
needed regarding effectiveness of the GFD and why parents who try the diet choose to 
continue or discontinue it.
More than 20% of young children with ASD have been tried on a GFD. Despite a lack of 
rigorous evidence that GFDs broadly impact ASD symptoms, this diet may still be used in 
an attempt to reduce GI or ASD symptoms. Children with ASD who had parent-reported 
developmental regression or GI issues were more likely to have used a GFD, yet 
developmental regression was more strongly associated with GFD when a child did not have 
GI issues. GFDs are necessary for treating celiac disease and may be appropriate for 
children with other GI issues, but effectiveness for treating ASD or other conditions deserves 
further study so that parents can make informed decisions about whether their child may 
benefit from this diet. Because GFD use is high and efficacy is uncertain, more information 
about the effect of a GFD on GI and ASD symptoms is needed so that clinicians can better 
advise parents of children with ASD.
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Lay summary
Gluten free diets are commonly used as an alternative therapy for autism spectrum 
disorder (ASD); however, the effectiveness is still uncertain which makes it important to 
know who tries this type of diet. We found that one in five preschool aged children with 
ASD had ever used a gluten free diet. Children with gastrointestinal conditions and 
developmental regression were more likely to have tried a gluten free diet.
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Figure 1. 
Prevalence ratios between associated features and ever use of a gluten free diet by whether 
the child ever had gastrointestinal issues among children 3–5 years old with autism spectrum 
disorder in the Study to Explore Early Development GI+, child ever having gastrointestinal 
issue; GI-, child never having gastrointestinal issue; ASD, autism spectrum disorder
Adjusted for maternal race/ethnicity, maternal education, and maternal age at clinic visit, 
child year of birth using inverse probability weights; site adjusted using random intercept
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Table 3
Prevalence ratios for the relationship between associated features and ever use of a gluten free diet among 
children 3–5 years old with autism spectrum disorder in the Study to Explore Early Development
Associated Feature Ever useN=130 %
Never use
N=559 % Prevalence Ratio 95% CI
Developmental regression
 Yes 42.3 25.6 1.70 1.23, 2.36
 No 67.7 74.4 – –
Intellectual disability
 Yes 61.5 62.3 0.92 0.77, 1.10
 No 38.5 37.7 – –
ASD severity
 >7 49.6 38.6 1.34 0.94, 1.91
 <7 50.4 61.4 – –
 Missing (n) 5 10 – –
Maternal gastrointestinal issues
 Yes 16.0 20.3 0.96 0.56, 1.65
 No 84.0 79.7 – –
 Missing (n) 1 19 – –
Child gastrointestinal issues
 Yes 78.3 47.0 2.95 2.31, 3.77
 No 21.7 53.0 – –
 Missing (n) 1 29 – –
GFD, gluten free diet; ASD, autism spectrum disorder; CI, confidence interval
Observations with missing data were dropped from the regression model
Adjustment for maternal race/ethnicity, maternal education, and maternal age at clinic visit, child year of birth using inverse probability weights; 
site adjusted using a random intercept
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